<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794142</url>
  </required_header>
  <id_info>
    <org_study_id>9459-2</org_study_id>
    <nct_id>NCT02794142</nct_id>
  </id_info>
  <brief_title>Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient</brief_title>
  <acronym>POPEYE</acronym>
  <official_title>Impact of the Oxidative Stress on the Skeletal Muscle Dysfunction in Hemodialysis Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hemodialysis patient (HD) a reduction of the skeletal muscle mass and strength has&#xD;
      previously been reported. This muscle impairment constitutes an independent prognosis factor&#xD;
      in HD patients. Oxidative stress and inflammation have been linked to the muscle impairment.&#xD;
      The mitochondria is a classical producer and target of reactive oxygen species (ROS), and may&#xD;
      thus constitute a central actor of the skeletal muscle impairment in HD patients. Therefore,&#xD;
      the aim of the present study is to investigate the role of the muscle mitochondrial density&#xD;
      on the muscle impairment in HD patients, in comparing the muscle mitochondrial density and&#xD;
      oxidative stress in HD patients vs. healthy matched controls.&#xD;
&#xD;
      In order to assess the effect of the oxidative stress and inflammation on the muscle&#xD;
      impairment in HD patients, muscle function assessements will be performed after renal&#xD;
      transplantation (which lowers the oxidative stress and inflammation levels) in the HD patient&#xD;
      group.&#xD;
&#xD;
      No therapeutic intervention will be tested in the present study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle mitochondrial density assessed on a quadriceps biopsy by immunochemistry</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum voluntary contraction of the quadriceps (in Newton.meter)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Renal Failure Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>HD patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>renal transplantation</intervention_name>
    <arm_group_label>HD patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40-80 years old&#xD;
&#xD;
          -  less than 150min by week of moderate to vigorous physical activity&#xD;
&#xD;
          -  Chronic renal failure (glomerular filtration rate less than 15mL by min) requiring&#xD;
             hemodialysis&#xD;
&#xD;
          -  Patient placed on the kidney transplant waiting list of MontpellierCHU&#xD;
&#xD;
          -  No indication against temporary kidney transplant&#xD;
&#xD;
          -  Review cardiovascular older than two years&#xD;
&#xD;
          -  Patient not under guardianship or trusteeship&#xD;
&#xD;
          -  Clinically stable state Absence or recent infection within 3 months prior to inclusion&#xD;
             Absence of progressive neoplasia No recent acute decompensation of chronic disease&#xD;
             (thrust of heart failure, respiratory decompensated cirrhosis).&#xD;
&#xD;
        Absence of recent stroke&#xD;
&#xD;
          -  musculoskeletal and neurological states of the lower limbs which allow the realization&#xD;
             of the proposed functional tests.&#xD;
&#xD;
          -  Patient has given written informed consent&#xD;
&#xD;
          -  Absence of congenital or genetic degenerative muscle disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal chronic renal failure without replacement therapy&#xD;
&#xD;
          -  Local anesthesic hypersensibility&#xD;
&#xD;
          -  Corticosteroid treatment upper than 3 month&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Oral anticoagulants&#xD;
&#xD;
          -  Previous renal transplantation&#xD;
&#xD;
          -  Subject not affiliated with a social security scheme, beneficiary or not such a plan&#xD;
&#xD;
          -  Major subject protected by law or unable to consent under Article L 1121-8 of the&#xD;
             Public Health Code&#xD;
&#xD;
          -  Vulnerable person under Article L.1121-6 of the Public Health Code&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>muscle dysfunction</keyword>
  <keyword>mitochondria</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <keyword>renal transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

